The Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates with high fatality rates. Ebola vaccines offer effective protection against the disease and help prevent outbreaks. These vaccines work by activating the body's immune system to recognize and fight the virus that causes Ebola. The global Ebola Vaccine Market is estimated to be valued at US$ 6.72 Bn in 2024 and is expected to exhibit a CAGR of 9.4% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growing demand for effective prevention against Ebola virus disease is a major trend propelling the Ebola Vaccine Market. Ebola virus outbreaks can spread rapidly with high mortality rates. Vaccines help safeguard communities at risk and aid relief efforts during outbreaks by preventing the spread of the deadly disease. They play a critical role in halting outbreaks and supporting recovery. Advanced Ebola vaccines under development also aim to provide cross-protection against the multiple species of the Ebola and Marburg viruses for longer-term immunity. This is expected to further boost adoption.
SWOT Analysis
Strength: A vaccine for Ebola offers strong protection against the deadly virus. It can help control outbreaks and save lives.
Weakness: Developing vaccines is an expensive process and it takes significant time and resources to conduct clinical trials. Limited manufacturing capabilities can also impact supply.
Opportunity: Recurring Ebola outbreaks in Africa present a continued need for vaccination programs in at-risk regions. Additional vaccines in the pipeline may capture new opportunities.
Threats: Resistance from parts of the population to accept vaccinations can reduce their effectiveness in managing outbreaks. Dependence on external aid also poses risks for vaccination programs' sustainability.
Key Takeaways
The global Ebola Vaccine Market Growth is expected to witness high growth over the forecast period of 2024 to 2031 supported by ongoing vaccination programs especially in Africa. The market was valued at US$ 6.72 billion in 2024 and is anticipated to reach US$ 12.67 billion by 2031, expanding at a CAGR of 9.4%.
Regional analysis indicates that demand for Ebola vaccines will remain high from Africa as the continent struggles to control periodic outbreaks of the deadly virus. Countries like Democratic Republic of Congo and Guinea where recent epidemics occurred are actively deploying vaccines. Organizations like WHO and UNICEF also contribute to the availability of vaccines in at-risk nations.
Key players operating in the Ebola vaccine market include 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode. These companies are focused on strengthening supply chains to fulfill international aid commitments as well as expanding their own production capacities. Partnerships are also gaining significance to achieve technology transfers necessary to locally manufacture vaccines especially for African requirements.
For more insights, read- https://www.insightprobing.com/ebola-vaccine-market-driven-by-rise-in-ebola-epidemics-globally/
For more details on the report, Read- https://masstamilan.tv/naloxone-life-saving-drug-in-opioid-overdose/
Comments
0 comment